HPRA completes inspection of Biocon Biologics new mAbs drug substance facility in Bengaluru

4 May 2022 , 10:33 AM

Biocon Biologics’s Spokesperson has announced in a press release that the Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP inspection of one of Biocon Biologics’ new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, India, between March 28 and April 1, 2022.

The inspection report contains no ‘critical’ observations and only one of the deficiencies is categorized as ‘major’ which is being addressed expeditiously in consultation with the regulatory agency.

The spokesperson further added, “This facility will help us address the additional requirements of our products in EU market.”

On Wednesday at around 10:34 AM, Biocon was trading at Rs370.60 apiece down by Rs2.05 or 0.55% from its previous closing of Rs372.65 apiece on the BSE.